Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040937 · ClinicalTrials.gov registry record · Phase 2

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
147
Enrollment target
20
Study locations

NCT00040937 is a Phase 2 study of Multiple Myeloma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 147 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040937, a Phase 2 study of Multiple Myeloma, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
147 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving thalidomide before and after peripheral stem cell transplant may be effective in treating newly diagnosed multiple myeloma. PURPOSE: This phase II trial is studying how well giving thalidomide with chemotherapy and peripheral stem cell transplant work in treating patients with newly diagnosed multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG cyclophosphamide
  • DRUG dexamethasone
  • DRUG melphalan
  • BIOLOGICAL filgrastim
  • BIOLOGICAL sargramostim

Study Locations (20)

Georgia

  • Piedmont Hospital - Atlanta
  • CCOP - Atlanta Regional - Atlanta
  • Northside Hospital Cancer Center - Atlanta
  • Saint Joseph's Hospital of Atlanta - Atlanta
  • WellStar Cobb Hospital - Austell
  • Charles B. Eberhart Cancer Center at DeKalb Medical Center - Decatur
  • Gwinnett Medical Center - Lawrenceville
  • Kennestone Cancer Center at Wellstar Kennestone Hospital - Marietta
  • Southern Regional Medical Center - Riverdale

Hawaii

  • Cancer Research Center of Hawaii - Honolula
  • OnCare Hawaii, Incorporated - Lusitana - Honolulu
  • Queen's Cancer Institute at Queen's Medical Center - Honolulu
  • Straub Clinic and Hospital, Incorporated - Honolulu
  • OnCare Hawaii, Incorporated - Kuakini - Honolulu
  • St. Francis Medical Center - Honolulu
  • Kapiolani Medical Center for Women and Children - Honolulu

California

  • University of California Davis Cancer Center - Davis
  • Sutter Roseville Medical Center - Roseville
  • Sutter Cancer Center - Sacramento

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2002-06
Est. Completion 2015-10
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00040937

The ClinicalTrials.gov registry entry for NCT00040937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00040937 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Hawaii, California.

Frequently Asked Questions

What is clinical trial NCT00040937 about?

NCT00040937 is a clinical study titled "S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma". RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give ...

What is the current status of trial NCT00040937?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2002-06. Estimated completion is 2015-10.

What conditions does trial NCT00040937 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00040937?

The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00040937?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00040937 being conducted?

This trial has 20 study locations across Arkansas, California, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.